Abstract: The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by subcutaneous injection. Uses, formulations and kits are also described.

Abstract: Methods and systems for processing telematics data are provided. In one embodiment, a method is provided that includes obtaining telematics information from a first device associated with a vehicle. The telematics information may indicate operations of the vehicle. An anomalous operation of the vehicle may then be determined based on the telematics information. The method may further include determining whether the anomalous operation of the vehicle is a vehicle collision. If the anomalous operation of the vehicle is a vehicle collision, routing information for the vehicle may be received that identifies previous locations of the vehicle. The routing information may then be compared with the telematics information to identify a location of the vehicle collision.

Abstract: Methods and systems for processing telematics data are provided. In one embodiment, a method is provided that includes obtaining telematics information from a first device associated with a vehicle. The telematics information may indicate operations of the vehicle. An anomalous operation of the vehicle may then be determined based on the telematics information. The method may further include determining whether the anomalous operation of the vehicle is a vehicle collision. If the anomalous operation of the vehicle is a vehicle collision, routing information for the vehicle may be received that identifies previous locations of the vehicle. The routing information may then be compared with the telematics information to identify a location of the vehicle collision.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: An aerosol composition comprising a propellant and a first particulate material comprising particles having a median aerodynamic diameter with the range 0.05 to 11 ?m, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume diameter within the range 15 to 200 ?m. The presence of the second particulate material provides good suspension properties, particularly where the propellant is a hydrofluoro alkane.

Abstract: The present invention relates to a method of treating a metastatic prostate cancer patient by administering to said patient an effective amount of a bicalutamide (4?-cyano-??,??,??-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide) containing formulation capable of delivering at least a mean steady state plasma level of (R)-bicalutamide enantiomer of 40 ?g/ml; and to bicalutamide containing products and formulations capable of delivering the at least mean steady state plasma level of (R)-bicalutamide enantiomer of 40 ?g/ml to a patient in need thereof.

Abstract: Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with the micelles of surfactant material. At least the dispersed phase is quenched to a solid state and the continuous phase and solvent are removed to produce the nanoparticles. The nanoparticles can be incorporated in an aerosol composition suitable for deep lung delivery by means of a metered dose inhaler.

Abstract: An aerosol composition comprising a propellant and a first particulate material comprising particle having a median aerodynamic diameter within the range 0.05 to 11 &mgr;m, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume diameter within the range 15 to 200 &mgr;m. The presence of the second particulate material provides good suspension properties, particularly where the propellant is a hydrofluoro alkane.

Abstract: Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with the micelles of surfactant material. At least the dispersed phase is quenched to a solid state and the continuous phase and solvent are removed to produce the nanoparticles. The nanoparticles can be incorporated in an aerosol composition suitable for deep lung delivery by means of a metered dose inhaler.